-+ 0.00%
-+ 0.00%
-+ 0.00%

Hansoh Pharma says China regulator accepts NDA for olatorepatide weight-loss injection

PUBT·06/04/2026 00:44:00
Listen to the news
Hansoh Pharma says China regulator accepts NDA for olatorepatide weight-loss injection
  • China’s NMPA accepted Hansoh Pharma’s NDA for once-weekly olatorepatide injection for chronic weight management in obese, overweight adults.
  • Phase 3 data showed up to 19.3% mean weight loss at week 48, with nausea below 10%.
  • Hansoh licensed ex-China rights to Regeneron in 2025, retaining Greater China commercialization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.